ArticleCancer immunology, immunotherapy : CII2023

Effects of the STAMP-inhibitor asciminib on T cell activation and metabolic fitness compared to tyrosine kinase inhibition by imatinib, dasatinib, and nilotinib.

Lukas Häselbarth et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.